LEDA Home Page HLSL Home PageLeda Search Results

Title: The Effects of False Claims Act Whistleblowers on the Pharmaceutical Industry (2006 Third Year Paper)
Author(s): Mark S. Davis
Subject & Subject keywords: Food and Drug Law "" "whistle blowers"
Abstract:The whistleblower (or “qui tam”) provisions of the False Claims Act allow private citizens to bring suit on behalf of the government against individuals or corporations who have submitted false or fraudulent claims to the government. Under the Act, a whistleblower is entitled to a percentage of the damages or settlement that the government ultimately receives as a result of the lawsuit. The qui tam provisions have been used with increasing frequency in recent years to initiate lawsuits against pharmaceutical manufacturers for fraud that these companies have allegedly committed against federal and state health care programs. This paper attempts to explain the effects that these whistleblower lawsuits have had upon the pharmaceutical industry. This paper also proposes ways that the False Claims Act and government enforcement efforts could be reformed in order to reduce both frivolous qui tam lawsuits and the need for such extensive False Claims Act prosecution.

PDF version (suitable for printing)
Davis06.pdf  (complete document)
HTML version (suitable for viewing with web browser)
Davis06.html  (complete document)
Rich Text Format version (suitable for use with word processor)
Davis06.rtf  (complete document)
ZIP'ped version (suitable for downloading)

Depositors authorize the Legal Information Institute to retain in perpetuity a digital copy of their scholarship and to provide, without charge, individual users of LEDA with the ability to view or print copies of a LEDA document for private, non-commercial use. Authors retain all other rights, including the rights of subsequent publication.